Zhou Jing, Yang Daofeng
Department of Infectious Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China.
J Hepatocell Carcinoma. 2023 Jun 2;10:821-831. doi: 10.2147/JHC.S411521. eCollection 2023.
HALP score consisting of hemoglobin content, albumin content, lymphocyte count, and platelet count can comprehensively evaluate the inflammatory response and nutritional status. Many researchers have indicated that the HALP score is an effective predictor of the overall prognosis of various tumors. However, there is no relevant research to suggest whether the HALP score can predict the prognosis of patients with hepatocellular carcinoma (HCC).
We retrospectively analyzed 273 HCC patients who underwent surgical resection. Hemoglobin content, albumin content, lymphocyte count, and platelet count in peripheral blood were measured for each patient. The relationship between the HALP score and overall survival (OS) was investigated.
With a mean of 56.69 ± 1.25 months follow-up, the 1-, 3-, and 5-year OS was 98.9%, 76.9%, and 55.3% for all patients, respectively. HALP scores (HR=1.708, 95% CI=1.192-2.448, P=0.004) were significant independent risk factors of OS. The 1-, 3-, and 5-year OS were 99.3%, 84.3%, and 63.4% for patients with high HALP scores; and 98.6%, 69.8%, and 47.5% for patients with low HALP scores, respectively (P=0.018). In TNM I-II stage patients, compared with high HALP scores, low HALP scores have worse OS (P=0.039). In AFP positive patients, compared with high HALP scores, low HALP scores have worse OS (P=0.042).
Our research showed the preoperative HALP score is an independent predictive factor of overall prognosis, and a low HALP score indicates a worse prognosis in HCC patients who underwent surgical resection.
由血红蛋白含量、白蛋白含量、淋巴细胞计数和血小板计数组成的HALP评分可全面评估炎症反应和营养状况。许多研究人员表明，HALP评分是各种肿瘤总体预后的有效预测指标。然而，尚无相关研究表明HALP评分是否可预测肝细胞癌（HCC）患者的预后。
我们回顾性分析了273例行手术切除的HCC患者。测量每位患者外周血中的血红蛋白含量、白蛋白含量、淋巴细胞计数和血小板计数。研究HALP评分与总生存期（OS）之间的关系。
平均随访56.69±1.25个月，所有患者的1年、3年和5年总生存率分别为98.9%、76.9%和55.3%。HALP评分（HR=1.708，95%CI=1.192-2.448，P=0.004）是总生存期的显著独立危险因素。HALP评分高的患者1年、3年和5年总生存率分别为99.3%、84.3%和63.4%；HALP评分低的患者分别为98.6%、69.8%和47.5%（P=0.018）。在TNM I-II期患者中，与HALP评分高的患者相比，HALP评分低的患者总生存期更差（P=0.039）。在甲胎蛋白阳性患者中，与HALP评分高的患者相比，HALP评分低的患者总生存期更差（P=0.042）。
我们的研究表明，术前HALP评分是总体预后的独立预测因素，HALP评分低表明接受手术切除的HCC患者预后较差。
